Chronic lymphocytic leukaemia

Michael Hallek, Tait D. Shanafelt, Barbara Eichhorst

Research output: Contribution to journalReview article

50 Scopus citations

Abstract

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.

Original languageEnglish (US)
Pages (from-to)1524-1537
Number of pages14
JournalThe Lancet
Volume391
Issue number10129
DOIs
StatePublished - Apr 14 2018
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Chronic lymphocytic leukaemia'. Together they form a unique fingerprint.

  • Cite this

    Hallek, M., Shanafelt, T. D., & Eichhorst, B. (2018). Chronic lymphocytic leukaemia. The Lancet, 391(10129), 1524-1537. https://doi.org/10.1016/S0140-6736(18)30422-7